NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.

John W RutlandCorey M GillJoshua LoewensternHanane AribMargaret PainMelissa UmphlettYayoi KinoshitaRussell B McBrideJoshua BedersonMichael DonovanRobert SebraRaj K ShrivastavaMary Fowkes

Published in: Cancer immunology, immunotherapy : CII (2020)

Our findings suggest that distribution of immune cell infiltration in meningiomas is associated with tumor mutational burden. NF2 mutational status was associated with an increasing density of scattered lymphocytes. As the role of immunotherapy in meningiomas continues to be elucidated with clinical trials that are currently underway, these results may serve as a novel biomarker of tumor mutational burden in meningiomas.

Keyphrases

clinical trial
signaling pathway
lps induced
oxidative stress
risk factors
nuclear factor
pi k akt
randomized controlled trial
peripheral blood
open label